Show simple item record

dc.creatorLezaić, Višnja
dc.creatorPetković, Nenad
dc.creatorMarić, Ivko
dc.creatorMiljković, Branislava
dc.creatorVučićević, Katarina
dc.creatorSimić-Ogrizović, Sanja
dc.creatorPejović, Vesna
dc.creatorĐukanović, Ljubica
dc.date.accessioned2019-09-02T11:33:22Z
dc.date.available2019-09-02T11:33:22Z
dc.date.issued2013
dc.identifier.issn0211-6995
dc.identifier.urihttp://farfar.pharmacy.bg.ac.rs/handle/123456789/1882
dc.description.abstractBackground: Balkan endemic nephropathy (BEN) hemodialysis patients require a higher dose of recombinant human erythropoietin for maintaining target hemoglobin level than patients with other kidney diseases. Objectives: Comparison of the pharmacokinetics of beta-erythropoietin given subcutaneously to hemodialysis patients with BEN or other kidney diseases (non-BEN). Methods: Recombinant human erythropoietin (75U/kg) was administered subcutaneously to 10 BEN and 14 non-BEN hemodialysis patients. The predose plasma level of erythropoietin (Epo) was subtracted from all postdose levels. The relevant pharmacokinetic parameters were calculated after noncompartmental pharmacokinetic analysis using Kinetica software (Thermo Scientific, ver.5.0). Results: Although basal plasma Epo concentration was similar in BEN (20.1 +/- 10.3U/L) and non-BEN (15.1 +/- 8.1U/L; p=.1964) patients, there were significant differences between the groups for elimination rate constant (0.016 +/- 0.006 vs 0.026 +/- 0.011 hr(-1); p=.020) and elimination half-life (50.24 +/- 19.12 vs 33.79 +/- 18.91 hr, p=.048). These differences remained significant after adjustment for patient characteristics (age, sex, hennodialysis duration, ferritin, PTH and ACEI use). No significant differences between groups were found in maximal Epo concentration, time to maximum Epo concentration, area under the curve from time of dosing extrapolated to infinity, clearance, mean residence time of Epo between groups both before and after adjustment. Conclusion: Pharmacokinetic analysis of beta-erythropoietin detected a significantly longer elimination half-life in BEN than in non BEN patients. This finding needs to be confirmed in a well-controlled study with a larger sample size.en
dc.publisherSoc Espanola Nefrologia Dr Rafael Matesanz, Madrid
dc.relationinfo:eu-repo/grantAgreement/MESTD/Basic Research (BR or ON)/175089/RS//
dc.rightsopenAccess
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceNefrologia
dc.subjectBalkan endemic nephropathyen
dc.subjectHuman recombinant erythropoietinen
dc.subjectPharmacokineticsen
dc.titleThe Pharmacokinetics of Recombinant Human Erythropoietin in Balkan Endemic Nephropathy Patientsen
dc.typearticle
dc.rights.licenseBY-NC-ND
dcterms.abstractЛезаић, Вишња; Вучићевић, Катарина; Симић-Огризовић, Сања; Марић, Ивко; Петковић, Ненад; Пејовић, Весна; Ђукановић, Љубица; Миљковић, Бранислава;
dc.citation.volume33
dc.citation.issue4
dc.citation.spage478
dc.citation.epage485
dc.citation.other33(4): 478-485
dc.citation.rankM23
dc.identifier.wos000330094500005
dc.identifier.doi10.3265/Nefrologia.pre2013.Apr.11800
dc.identifier.pmid23897179
dc.identifier.scopus2-s2.0-84883008692
dc.identifier.fulltexthttp://farfar.pharmacy.bg.ac.rs//bitstream/id/666/1880.pdf
dc.identifier.rcubconv_3002
dc.type.versionpublishedVersion


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record